Relieves inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. ANDA 207440, held by Rising. Diflorasone Diacetate.
As of Nov 15, 2026, ANDA 207440 (Diflorasone Diacetate), held by Rising, was first approved by FDA on Feb 27, 2017, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Topical corticosteroids are indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 27, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Diflorasone Diacetate0.05% · ointment;topical | Diflorasone Diacetate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
